First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B
Authors:
Open Access
- 25 October 2022
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 30 (12) , 3587-3600
Abstract
No abstract availableKeywords
Funding Information
- Sangamo Therapeutics
This publication has 45 references indexed in Scilit:
- The Liver as a Target Organ for Gene Therapy: State of the Art, Challenges, and Future PerspectivesPharmaceuticals, 2012
- Human Galectin 3 Binding Protein Interacts with Recombinant Adeno-Associated Virus Type 6Journal of Virology, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primatesMolecular Genetics and Metabolism, 2011
- Safety of Liver Gene Transfer Following Peripheral Intravascular Delivery of Adeno-Associated Virus (AAV)-5 and AAV-6 in a Large Animal ModelHuman Gene Therapy, 2011
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targetingNucleic Acids Research, 2011
- Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genomeGenome Research, 2010
- Biodistribution and Safety Profile of Recombinant Adeno-Associated Virus Serotype 6 Vectors following Intravenous DeliveryJournal of Virology, 2008
- Gene therapy for haemophiliaBritish Journal of Haematology, 2008